|
|
|
|
|
Efalizumab
drug data and news
Efalizumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Efalizumab | ||
| Brand Names/Synonyms | Raptiva; hu1124; antiCD11 alpha; anti alphaL integrin; Raptiva (Genentech Inc) | ||
| Indication | For treatment of psoriasis | ||
| Sponsored links | Description | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. | |
| Pharmacology | Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types. | ||
| Mechanism Of Action | Raptiva binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result Raptiva decreases cell surface expression of CD11a. | ||
| Efalizumab News (When available) |
XOMA Announces March 9 Discussion of 2005 Financial Results 06 Mar 2006 XOMA Announces Successful Exchange Offer With A Tender of 100% of ... Feb 9, 2006 Flat sales in Q4 for Serono; no word on buyer Feb 6, 2006 Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006 Emory awarded grant for diabetes research Feb 2, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Immunomodulatory Agents; Immunosupressants | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Humanized anti-CD11a antibody | ||
| Chemical Formula | Not Available | ||
| Molecular Weight | Not Available | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Efalizumab.html http://www.rxlist.com/cgi/generic3/raptiva.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00074 | ||
| CAS Registry Number | 214745-43-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10304 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |